J3580

JNJ 17203212

≥98% (HPLC)

• Synonim(y): N¹-(3-Trifluoromethylpyrid-2-yl)-N⁴-(4-trifluoromethylpyrid-2-yl)carbamoylpiperazine
• Wzór empiryczny (zapis Hilla): C₁₇H₁₅F₆N₅O
• Numer CAS: 821768-06-3
• Masa cząsteczkowa: 419.32
• UNSPSC Code: 12352200
• Assay: ≥98% (HPLC)
• Form: powder

Właściwości

• assay: ≥98% (HPLC)
• form: powder
• color: white to off-white
• solubility: DMSO: >20 mg/mL
• originator: Johnson & Johnson
• storage temp.: −20°C
• SMILES string: FC(F)(F)c1c(nccc1)N2CCN(CC2)C(=O)Nc3ncc(cc3)C(F)(F)F
• InChI: 1S/C17H15F6N5O/c18-16(19,20)11-3-4-13(25-10-11)26-15(29)28-8-6-27(7-9-28)14-12(17(21,22)23)2-1-5-24-14/h1-5,10H,6-9H2,(H,25,26,29)
• InChI key: JFRYYGVYCWYIDQ-UHFFFAOYSA-N

Opis

Biochem/physiol Actions

JNJ 17203212 is a reversible, competitive and potent TRPV1 antagonist that does not inhibit related TRP channels such as TRPV2, TRPV4, or TRPA1. Listed in BJP with IC50= 65 nM. TRPV1 channels are activated by heat, capsaicin and the endocannabinoid anandamide. Interest in TRPV1 antagonists in the transmission and modulation of pain.

JNJ 17203212 is a reversible, competitive and potent TRPV1 antagonist.

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Ta strona może zawierać tekst przetłumaczony maszynowo.

Informacja o środkach bezpieczeństwa

• pictograms: GHS06
• signalword: Danger
• hcodes: H301,H319
• pcodes: P301 + P310 + P330 - P305 + P351 + P338
• Hazard Classifications: Acute Tox. 3 Oral - Eye Irrit. 2
• Klasa składowania: 6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable